The T-cell engager blinatumomab (Blincyto, Amgen) was characterized as new standard in pediatric B-cell acute lymphoblastic leukemia (B-ALL) based on a phase 3 trial that was terminated early due to evidence that established benefit at the interim analysis.
When added to standard chemotherapy, blinatumomab increased three-year disease-free survival past 95% and the benefit was observed in newly diagnosed children with either standard or higher-risk B-ALL, reported Rachel E. Rau, MD, an associate